<DOC>
	<DOC>NCT00643448</DOC>
	<brief_summary>Explorative study in Atrial Fibrillation patients to assess Safety and Pharmacokinetics at initiation of treatment and at steady state</brief_summary>
	<brief_title>Explorative Study of AZD1305 in Atrial Fibrillation Patients</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Documented Atrial Fibrillation but in stable SR for at least 2 h and a maximum of 28 days. Sinus rhythm at randomisation Haemodynamically unstable condition as judged by the Investigator, systolic BP &lt;100 mmHg or &gt;180 mmHg, or diastolic BP &gt;105 mmHg at randomisation Personal or family history of Torsades de Pointes (TdP), any other polymorphic ventricular tachycardia (PVT), sustained ventricular tachycardia, long QT syndrome and/or Brugada syndrome Sinus bradycardia (&lt;50 beats per minute (bpm)) at randomisation QTc (Fridericia, QTcF ) &gt;450 ms measured in sinus rhythm at randomisation, Serum potassium below 3.8 or above 5.0 mmol/L or plasma potassium below 3.6 or above 5.0 mmol/L QRS duration &gt;120 ms at randomisation Use of any antiarrhythmic drug class I and/or III, digitalis glycoside, QT prolonging drug and/or drug that inhibits CYP3A4, as well as St John's Worth</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>